Eurocor in Barcelona: CIRSE 2016
Visit our Exhibition Stand #93 at the International Congress of Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Eurocor will be present at the annual meeting of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Barcelona, Spain. CIRSE congress 2016 is dedicated to improve patient care through the support of teaching, science, research and clinical practice in the field of cardiovascular and interventional radiology from September 10th – 14th 2016. Eurocor is looking forward to show visitors innovative endovascular devices such as FREEWAY™ 014 and 035 peripheral drug-eluting balloon.
Eurocor FREEWAY™ – COATED SHUNT BALLOON CATHETER launch. Now CE marked.
The balloon is indicated for patients who undergo dialysis as they suffer from end stage renal failure. Stenosis and subsequent restenosis of the dialysis shunt graft is a common complication. The treatment of this stenosis is mandatory to protect AV fistulas and shunt grafts from early restenosis.
High pressure balloon is recommended for the treatment of AV fistulas, and shunt grafts as it reduces re-intervention and preserves future treatment options.
Eurocor Scientific Program
Two abstracts for the Freeway studies have been submitted to CIRSE and both have been accepted for oral presentation
1.) DEB and stents: what we have learnt from the Freeway Stent Study and the PACUBA Trial
J. Lammer, J. Tacke
FP 1408 - Peripheral 1
Sunday, September 11, 2016, 16:15 - 17:15; Room 116
2.) The Freeway Stent Study: the 6-month results favor the use of DEB in combination with stenting
J. Tacke, K.A. Hausegger, H. Schröder, S. Müller-Hülsbeck, S. Stahnke
FP 3106 - Peripheral 2
Tuesday, September 13, 2016, 17:30 - 18:30; Room 114
The coating makes the difference. Eurocor drug-eluting balloons have a unique homogeneous coating. The coating done by Eurocor consists of a 1:1 mixture of Shellac and Paclitaxel. The natural resin of Shellac is broad on the balloon in a 1:1 mixture and hardens the balloon surface. Due to this effect the Eurocor drug-eluting balloons are non-crystalline and are showing nearly no wash out effect.
FREEWAY™ uses the same technology as Eurocor’s DIOR® paclitaxel-eluting coronary balloon but applies it to a new patient population. Eurocor’s latest second-generation drug-eluting technology PTA balloon FREEWAY™ has been developed as an alternative to address the limitations of existing therapeutic to PAD e.g. restenosis after POBA or stenting (ISR) . FREEWAY™ is available in two versions: 014 and 035.
Meet Eurocor in Barcelona at CIRSE 2016.
Further information on http://www.cirse.org and Eurocor.de
Eurocor is a rapidly growing European Life Sciences Technology Corporation specializing in the research, development and manufacture of cardiovascular and endovascular products. Eurocor provides interventional physicians with innovative coronary stent technologies and special cardiovascular and endovascular devices, manufactured in Europe. Products are indicated for minimally cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Extensive research and development, close clinician collaboration, outstanding quality standard philosophy and global scientific alliances lead to optimization of clinically effective technologies. Eurocor has designed an innovative method for balloon catheter drug delivery with high patient compliance. One heartbeat ahead® – with innovative products such as DIOR® and FREEWAY™.
Eurocor GmbH is a wholly owned subsidiary of Opto Eurocor Healthcare Limited and is part of Opto Circuits Group
For more information, please visit eurocor.de and optocircuits.com